Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy

We investigated the predictors of plasma mid-dose concentrations (C12) of efavirenz by enrolling 456 HIV-positive patients who had received 2 nucleos(t)ide reverse-transcriptase inhibitors plus efavirenz (600 mg daily) for 2 weeks or longer and had their CYP2B6 516G>T polymorphism and efavirenz C...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Sung-Hsi, Lin, Shu-Wen, Chang, Sui-Yuan, Lin, Ya-Ting, Chiang, Chieh, Hsiao, Chin-Fu, Sun, Hsin-Yun, Liu, Wen-Chun, Su, Yi-Ching, Hung, Chien-Ching, Chang, Shan-Chwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701031/
https://www.ncbi.nlm.nih.gov/pubmed/29170492
http://dx.doi.org/10.1038/s41598-017-16483-2

Ejemplares similares

Ejemplares similares